Boenning & Scattergood Starts Elite Pharmaceuticals (ELI) at Market Outperform
ELI Hot Sheet
Rating Summary:0 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 16 | Down: 7 | New: 23
Boenning & Scattergood initiates coverage on Elite Pharmaceuticals Inc. (AMEX: ELI) with a Market Outperform rating and $4 price target.
Analyst Debjit Chattopadhyay, Ph.D said, "We believe Elite is poised to advance two pain products into Phase III trials later this year, which we think could lead to significant commercialization deals."
Analyst Debjit Chattopadhyay, Ph.D said, "We believe Elite is poised to advance two pain products into Phase III trials later this year, which we think could lead to significant commercialization deals."
You May Also Be Interested In
- UPDATE: William Blair Starts EPIQ Systems (EPIQ) at Outperform; Broad Suite of Solutions in Electronic Discovery Sector
- Barclays Cuts Estimates and Price Target on ADP (ADP); Mixed Data From Investor Day
- Piper Jaffray Starts Life Technologies (LIFE) at Neutral
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
